The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global orthobiologics market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 5% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Orthobiologics are tissue-derived products made using substances that are naturally found in the body, such as carbohydrates, proteins, cells, and glycoproteins. They assist in reducing pain and inflammation, reversing debilitating effects of osteoarthritis, and facilitating the process of cartilage regeneration, tendon healing, ligament repairing, and bone formation. Some of the commonly utilized orthobiologic therapies are stem cells, platelet-rich plasma (PRP), autologous conditioned plasma (ACP), and bone marrow aspirate concentrate (BMAC). Amongst these, PRP is gaining traction across the globe as novel treatment modalities with minimal side effects in diverse musculoskeletal conditions. These conditions include rotator cuff tears, sub-acromial impingement, shoulder osteoarthritis, patellar tendinosis, lateral epicondylar tendinopathy, and knee osteoarthritis.
Orthobiologics aid in the quick recovery of sports-related injuries among professional and recreational athletes. The increasing participation of individuals in sports and physical activities represents one of the major factors influencing the market positively. Apart from this, rotator cuff tears can appear among older people due to degenerative changes in the body. This, in confluence with the growing geriatric population, is impelling the market growth. Moreover, the risk of developing osteoarthritis can be increased due to sedentary lifestyles, unhealthy dietary patterns, and the prevalence of chronic diseases. In addition, several orthobiologics utilized for invasive surgeries can be reimbursed under insurance coverage, which is strengthening the market growth. Furthermore, the growing awareness about the benefits associated with orthobiologic therapies, such as avoiding major invasive surgery like joint replacement and fast recovery time, is promoting their adoption over other surgical procedures. Besides this, the increasing number of orthopedic surgeries and the escalating demand for bioabsorbable implants for fracture fixation is contributing to the use of orthobiologics, such as autograft and allograft bone, and demineralized bone matrix, among the pediatric population.
IMARC Group provides an analysis of the key trends in each sub-segment of the global orthobiologics market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on product, type, application and end user.
Breakup by Product:
Breakup by Type:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Arthrex Inc, Globus Medical Inc., Integra LifeSciences, Johnson & Johnson, Medline Industries Inc., Medtronic plc, NuVasive Inc, Orthofix Medical Inc., Smith & Nephew plc, Stryker Corporation, Terumo Corporation, Wright Medical Group N.V. and Zimmer Biomet.
|Base Year of the Analysis||2020|
|Segment Coverage||Product, Type, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Arthrex Inc, Globus Medical Inc., Integra LifeSciences, Johnson & Johnson, Medline Industries Inc., Medtronic plc, NuVasive Inc, Orthofix Medical Inc., Smith & Nephew plc, Stryker Corporation, Terumo Corporation, Wright Medical Group N.V. and Zimmer Biomet.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at